Company news

EyePoint, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors

June 22, 2022

EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

June 20, 2022

EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual Meeting

June 9, 2022

EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference

May 16, 2022

EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

May 3, 2022

EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan

May 3, 2022

EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

April 26, 2022

EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

April 20, 2022

EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank

March 8, 2022

EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

March 6, 2022

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments

March 2, 2022

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference

February 28, 2022

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

February 23, 2022

EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

February 11, 2022

EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

January 9, 2022

EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements

January 9, 2022

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®

December 6, 2021

EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

November 18, 2021

EyePoint Pharmaceuticals Announces Pricing of Public Offering

November 15, 2021

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

November 12, 2021

EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD

November 4, 2021

EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

November 2, 2021

EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer

October 31, 2021

EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021

October 26, 2021

EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting

October 11, 2021

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

September 16, 2021

EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

August 9, 2021

EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

August 3, 2021

EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board

August 1, 2021

EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021

July 27, 2021

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

July 19, 2021

EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD

July 5, 2021

EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association

June 30, 2021

EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index

June 27, 2021

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

May 25, 2021

EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMD

May 24, 2021

EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments

May 4, 2021

EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021

April 27, 2021

EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments

March 3, 2021

EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021

February 24, 2021

EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock

February 3, 2021

EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 31, 2021

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD

January 27, 2021

EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues

January 10, 2021

EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics

January 2, 2021

EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings Corporation

December 17, 2020

EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split

December 7, 2020

EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration

December 2, 2020

EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4

November 18, 2020

EyePoint Pharmaceuticals Presents Positive Data of YUTIQ® and DEXYCU® in Four Poster Sessions at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

November 15, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.